๊ธฐ๋ณธ ์ •๋ณด

  • ๋‰ด์บ์Šฌ๋ณ‘ : ๋ฐ”์ด๋Ÿฌ์Šค์„ฑ ์งˆ๋ณ‘. ํ˜ˆ๊ตฌ์‘์ง‘๋Šฅ(hemagglutinating)์ด ์žˆ์Œ
  • v(virulent) ND๋Š” notifiable disease๋กœ, ๋ฐœ๊ฒฌ ์ฆ‰์‹œ ์‹ ๊ณ ํ•ด์•ผ ํ•จ.
  • ์ธ์ˆ˜๊ณตํ†ต๊ฐ์—ผ๋ณ‘์œผ๋กœ ๊ฒฐ๋ง‰์—ผ(conjunctivitis)์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ์ง€๋งŒ, human-to-human spread๋Š” X
  • ๋ถ„๋ฅ˜
  1. Doyleโ€™s form (vvND) : viscerotropic velogenic
    • ๊ธ‰์„ฑ, ์น˜๋ช…์ , ์žฅ์—์„œ ์ถœํ˜ˆ
  2. Beachโ€™s form (NVND) : neurotropic velogenic
    • ๊ธ‰์„ฑ, ์ข…์ข… ์น˜๋ช…์ , ํ˜ธํก๊ธฐ์™€ ์‹ ๊ฒฝ๊ณ„ ์ชฝ ๋ฌธ์ œ๋ฅผ ์ผ์œผํ‚ด
  3. Beaudetteโ€™s form : mesogenic
    • NVND์˜ ์ค‘๊ฐ„ ๋…์„ฑ ๋ฒ„์ „, ์–ด๋ฆฐ ์กฐ๋ฅ˜๋Š” ์ฃฝ๊ธฐ๋„ ํ•จ
  4. Hitchnerโ€™s form : lentogenic
    • ํ˜ธํก๊ธฐ ๊ฐ์—ผ์ด์ง€๋งŒ ๋ณ‘์›์„ฑ์ด ๋‚ฎ์Œ, live ๋ฐฑ์‹ ์œผ๋กœ ์ด์šฉ
  5. Asymptomatic-enteric form : apathogenic
    • ์žฅ๊ด€ ๊ฐ์—ผ์ด์ง€๋งŒ ๋ณ‘์›์„ฑ ๋‚ฎ๊ณ  ๋ฌด์ฆ์ƒ, live ๋ฐฑ์‹ ์œผ๋กœ ์ด์šฉ
  • Family Paramyxoviridae, Subfamily Paramyxovirinae, Genus Orthoavulavirus
    • ๋‰ด์บ์Šฌ๋ณ‘์€ 13๊ฐœ์˜ serotype ์ค‘ 1๋ฒˆ์งธ (APMV-1)

ํŠน์„ฑ

  • ๋‹คํ˜•์„ฑ, (-) ssRNA
  • 6 structural proteins : NP-P-M-F-HN-L
    • HN : Hemagglutinin(ํ˜ˆ๊ตฌ ์‘์ง‘) & Neuraminidase activities(virus release). host cell์˜ sialic acid์— ๋ถ€์ฐฉํ•˜๋Š” ์—ญํ• 
    • F : Fusion. viral & cell membrane ์œตํ•ฉ.
    • M : membrane. core๊ณผ envelope ์‚ฌ์ด์˜ ๊ณต๊ฐ„์„ ๋ฉ”์›Œ virus ํ˜•ํƒœ ์œ ์ง€.
    • NP : Nucleocapsid protein. NP์˜ ๋†๋„๊ฐ€ ๋†’์•„์ง€๋ฉด ๋ณต์ œ, ๋†๋„๊ฐ€ ๋‚ฎ์•„์ง€๋ฉด ์ „์‚ฌ๊ฐ€ ์ผ์–ด๋‚จ.
    • P : Phosphoprotein. RNA editing์— ๊ด€์—ฌ.
    • L : Large protein. RNA-directed RNA-polymerase ์—ญํ• (โ†’ Replication)
  • Non-enveloped virus๊ฐ€ ์†Œ๋…์ œ ์ €ํ•ญ์„ฑ์ด ๋” ๊ฐ•ํ•˜๋‹ค. ND๋Š” Enveloped virus๋ผ ์†Œ๋…์ œ์— ์•ฝํ•˜๋‹ค. (common disinfectants์— ์‰ฝ๊ฒŒ inactivation)

replication of NDV in respiratory cell

  1. attachment : HN
  2. fusion : F
  3. replication : RNA-directed RNA-polymerase)
  4. budding : cell surface

Strain classification

  1. Antigenicity(ํ•ญ์›์„ฑ) test
    • VN(Virus Neutralization) : ฮฑ-A ํ•ญ์ฒด์™€ B virus๋ฅผ ํ•ฉ์ณ ์„ธํฌ์— ์ ‘์ข…ํ–ˆ์„ ๋•Œ, CPE๊ฐ€ ๋‚˜ํƒ€๋‚˜๋ฉด ์ค‘ํ™”๋˜์ง€ ์•Š์€ ๊ฒƒ์œผ๋กœ, A virus๊ฐ€ ์•„๋‹ˆ๋ผ ๋‹ค๋ฅธ virus์ž„์„ ์•Œ ์ˆ˜ ์žˆ์Œ.
    • Agar gel diffustion : agar gel์— ๋‹ค์–‘ํ•œ ํ•ญ์ฒด๋ฅผ ๋„ฃ๊ณ , ๋ฏธ์ง€์˜ virus๋ฅผ incubation โ†’ ์–ด๋–ค ํ•ญ์ฒด์™€ ๊ฒฐํ•ฉํ•ด์„œ ์ค‘ํ™”๋˜๋Š”์ง€ ํ™•์ธ
    • MAb(Monoclonal antibody) : virus๋ฅผ ์ ‘์ข…ํ•ด์„œ MAb๋ฅผ ์–ป์Œ โ†’ ํ˜•๊ด‘ ์—ผ์ƒ‰ ๋“ฑ์œผ๋กœ ํ™•์ธ
  2. Pathogenicity(๋ณ‘์›์„ฑ) test
    • MDT(Mean Death Time) : virus๋ฅผ ๊ณ„ํƒœ์•„์ข…๋ž€์— ์ ‘์ข…ํ–ˆ์„ ๋•Œ ์–ผ๋งˆ๋‚˜ ๋นจ๋ฆฌ ์ฃฝ๋Š”๊ฐ€
      • Apathogenic(150์ด์ƒ) - Lentogenic(90-150) - Mesogenic(60-90) - Velogenic(60์ดํ•˜)
    • ICPI(Intracerebral Pathogenicity Index) : SPF ๋‹ญ์˜ ๋Œ€๋‡Œ์— ์ ‘์ข…ํ–ˆ์„ ๋•Œ ์–ผ๋งˆ๋‚˜ ๋นจ๋ฆฌ ์ฃฝ๋Š”๊ฐ€
    • IVPI(Intravenous Pathogenicity Index) : SPF ๋‹ญ์˜ ์ •๋งฅ ๋‚ด์— ์ ‘์ข…ํ–ˆ์„ ๋•Œ ์–ผ๋งˆ๋‚˜ ๋นจ๋ฆฌ ์ฃฝ๋Š”๊ฐ€
  3. plaque formation
  4. elution
  5. thermostability
  6. structure polypeptide
  7. oligonucleotide fingerprinting
  8. lectin binding
  9. genetic characterization

MDT level - phatogenic of NDV

pathogenicityMDT level
velogenic< 60H
mesogenic60-90H
lentogenic> 90H
asymptomatic> 90H

60์‹œ๊ฐ„ ์ด๋‚ด์— ์ฃฝ์œผ๋ฉด velogenic/highly pathogenic

ICPI level - phatogenic of NDV

pathogenicityICPI level
velogenic1.5-2.0
mesogenic1.0-1.5
lentogenic0.2-0.5
asymptomatic0.0-0.2

OIE ๊ธฐ์ค€ - NDV virulence

  • ICPI 0.7 ์ด์ƒ
  • at least 3 arginine or lysine residues between amino acid residues 113 and 116 of the NDV F

๋ถ€๊ฒ€์†Œ๊ฒฌ(Gross Lesions)

  • ์ˆ™์ฃผ์˜ ๋‚˜์ด์™€ ๋ฉด์—ญ ์ƒํƒœ
  • lymphoid patch์˜ necrosis์™€ hemorrhage
  • cecal tonsil์˜ ๋น„๋Œ€
  • ๋‚œํฌ์„ฑ ๋ณต๋ง‰์—ผ(egg yolk peritonitis), peritonitis with fibrin deposition(follicle์ด ๋ณต๊ฐ•์œผ๋กœ ๋–จ์–ด์ง)
  • stigma์— ์ถœํ˜ˆ
  • proventriculus์— ์ถœํ˜ˆ

clinical signs of VVND & NVND

  • vvND : ์‹ฌ๊ฐํ•œ ํ˜ธํก๊ธฐ์ฆ์ƒ, ๋ˆˆ, ์–ผ๊ตด ์ชฝ์— edema, ๋…น๋ณ€(์ดˆ๋ก์ƒ‰ ์„ค์‚ฌ), muscular tremer(์‚ฌ๊ฒฝ ์ „ ๊ทผ์œก๊ฒฝ๋ จ), torticollis(์‚ฌ๊ฒฝ), ์‚ฐ๋ž€์œจ ์ €ํ•˜, mortality 0-100%
  • NVND : ์‹ ๊ฒฝ์ฆ์ƒ 1-2์ผ ํ›„ ์‹ฌ๊ฐํ•œ ํ˜ธํก๊ธฐ์ฆ์ƒ, ์‚ฐ๋ž€์œจ ์ €ํ•˜, ์„ค์‚ฌ

Diagnosis(์ง„๋‹จ)

isolation and identification of NDV

  • isolation : ์‚ด์•„์žˆ๋Š” ์ƒํƒœ๋กœ virus ๋ถ„๋ฆฌ
  • identification : ๊ฒ€์ฒด ๋‚ด virus ์กด์žฌ ํ™•์ธ, ๋™์ •
  1. ํ˜ธํก๊ธฐ๋‚˜ ๋ฐฐ์„ค๊ฐ• ์ชฝ swab, ๋ถ€๊ฒ€ ์†Œ๊ฒฌ์ด ํ™•์—ฐํžˆ ๋ณด์ด๋Š” ์กฐ์ง๋“ค์„ sampling
  2. 9-11 day chick eggs์˜ allantoic sac์— ์ ‘์ข…ํ•˜์—ฌ 2-7์ผ ๋ฐฐ์–‘
  3. HA(hemagglutination) test
    • HA : RBC ์‘์ง‘๋Šฅ. virus์˜ HN glycoprotein๊ณผ RBC์˜ receptor๊ฐ€ ๋ฐ˜์‘
    • HA ๊ฐ€ ๋‚˜ํƒ€๋‚˜๋ฉด, virus๊ฐ€ relase๋จ. NDV strain์— ๋”ฐ๋ผ elution rate๊ฐ€ ๋‹ค๋ฆ„. (B1 strain์€ La Sota๋ณด๋‹ค ๋น ๋ฆ„)
    • qualitative HA(์ •์„ฑ๋ถ„์„) : ํ˜ˆ๊ตฌ์‘์ง‘์ด ๋‚˜ํƒ€๋‚˜๋Š”์ง€ ํ™•์ธ.
    • quantitative HA(์ •๋Ÿ‰๋ถ„์„) : ๋ฐ”์ด๋Ÿฌ์Šค๋ฅผ 2๋ฐฐ์”ฉ ํฌ์„ํ•˜์—ฌ ๋ฐ˜์‘ ์ง„ํ–‰
    • prozone reaction : ๋ฐ”์ด๋Ÿฌ์Šค๊ฐ€ ๋„ˆ๋ฌด ๋งŽ์•„์„œ ํ˜ˆ๊ตฌ ์‘์ง‘์ด ๋‚˜ํƒ€๋‚˜์ง€ ์•Š๋Š” ํ˜„์ƒ. RBC์˜ ๋ชจ๋“  sialic acid๊ฐ€ ๋ฐ”์ด๋Ÿฌ์Šค์™€ ๊ฒฐํ•ฉ โ†’ RBC๋ผ๋ฆฌ ์—ฐ๊ฒฐ๋˜์ง€ X
  4. VN(virus neutralizaiton) test

Antigen detection

  1. IFA/FA : (in)direct fluorescence, ๊ฒ€์ฒด์— mAb๋ฅผ ๋ถ™์ธ ๋’ค, ํ˜•๊ด‘๋ฌผ์งˆ์ด ๋ถ™์€ ์ด์ฐจํ•ญ์ฒด๋ฅผ ๋ถ™์ž„
  2. IP : immunoperoxidase. ๋ฉด์—ญ ์—ผ์ƒ‰
  3. Ag-capture :
  4. PCR

Serology

HI(Hemagglutination-inhibition) test

HI level - mortality ๊ด€๊ณ„ (after vvnDV challenge)

HI levelsmortality
~2^2100%
2^2~2^510%
2^4~2^60%
2^6~2^8no death, ์‹ฌ๊ฐํ•œ ์‚ฐ๋ž€์œจ ์ €ํ•˜
2^9~2^11no death, ์‚ฐ๋ž€์œจ ์ €ํ•˜X
2^11~2^13ํ–ฅํ›„ 6๊ฐœ์›”๊ฐ„ ์‚ฐ๋ž€์œจ ์ €ํ•˜ ๊ฑฑ์ •X

immune response against NDV

  • most protein appears to be antibody mediated against HN glycoprotein
  • cell mediated immunity(CMI) involve in viral clearance
  • local immunity(IgA, haderian gland ๋“ฑ)๊ฐ€ ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•จ.